The discovery of the high frequency of mutation in melanoma BRAF protein (over 50% of cases show BRAFV600E) set off the development of target-specific drugs, a strategy that was expected to overcome all barriers of toxicity and resistance faced until then [14]. The gene discussed is BRAF; the disease is melanoma.